James Hambro & Partners purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,928 shares of the company’s stock, valued at approximately $360,000.
Several other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Eli Lilly and by 51.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock valued at $2,042,017,000 after acquiring an additional 4,082,728 shares during the period. Norges Bank purchased a new stake in shares of Eli Lilly and in the 4th quarter valued at approximately $1,463,293,000. Janus Henderson Group PLC raised its stake in shares of Eli Lilly and by 5.2% in the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock valued at $1,034,108,000 after acquiring an additional 302,296 shares during the period. Fisher Asset Management LLC raised its stake in shares of Eli Lilly and by 9.3% in the 1st quarter. Fisher Asset Management LLC now owns 5,508,308 shares of the company’s stock valued at $1,029,062,000 after acquiring an additional 470,518 shares during the period. Finally, California Public Employees Retirement System increased its stake in Eli Lilly and by 2.5% during the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock worth $772,504,000 after buying an additional 110,280 shares during the period. 75.59% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on the stock. Bank of America upped their target price on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, January 22nd. Mizuho cut their target price on shares of Eli Lilly and from $228.00 to $216.00 and set a “buy” rating on the stock in a research note on Tuesday. Truist upped their target price on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Barclays cut their target price on shares of Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Morgan Stanley cut their target price on shares of Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Buy” and a consensus price target of $200.75.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Monday, April 26th. The company reported $1.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.12 by ($0.25). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company had revenue of $6.81 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the previous year, the company posted $1.75 EPS. The company’s quarterly revenue was up 16.1% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 10th. Stockholders of record on Friday, May 14th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 1.83%. Eli Lilly and’s payout ratio is 56.29%.
In related news, CAO Donald A. Zakrowski sold 3,000 shares of the stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the sale, the chief accounting officer now owns 5,987 shares in the company, valued at approximately $1,085,922.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jackson P. Tai purchased 1,366 shares of the firm’s stock in a transaction that occurred on Friday, April 30th. The shares were acquired at an average price of $182.84 per share, with a total value of $249,759.44. Following the purchase, the director now owns 60,649 shares in the company, valued at $11,089,063.16. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Recommended Story: What is an economic bubble?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.